Skip to content

Price / book at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
CG Oncology logo
CG OncologyCGON
5.2×+2.6×
Arvinas logo
ArvinasARVN
1.8×+1.0×
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
14.4×+3.5×
Replimune Group logo
Replimune GroupREPL
3.6×+1.7×

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s price / book?
Relmada Therapeutics, Inc. (RLMD) reported price / book of 3.3× in Q1 2026.
How has Relmada Therapeutics, Inc.'s price / book changed year-over-year?
Relmada Therapeutics, Inc.'s price / book increased by 735.7% year-over-year, from 0.4× to 3.3×.
What is the long-term trend for Relmada Therapeutics, Inc.'s price / book?
Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s price / book has grown at a -13.4% compound annual growth rate (CAGR), from 8.4× to 4.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.